Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Our proprietary technology platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets. Applying this technology to disease targets that are not adequately addressed by traditional therapeutic approaches, we are developing a robust pipeline of novel therapies for patients with unmet medical needs.
Brian J. G. Pereira, MD
President & CEO
Brian J. G. Pereira, MD joined Visterra in 2013 and is a veteran biopharmaceutical and healthcare leader with experience in financing and growing companies. Prior to joining Visterra, Brian served as the President and CEO of AMAG Pharmaceuticals.
275 2nd Avenue
Waltham, MA 02451